Skip to content

BIOADAPTIVES, INC.

BDPT · OTCM

CIK 1575142fmd_1PQBX87X5XJCK16SJZXDK6BHS1Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2013 to Jun 30, 2026, 48 periods

Latest annual · FY2025

Millions
Total revenues
0
Gross profit
0
Operating income
(1)
Net income
(2)
Free cash flow
(1)

Latest quarter · Q2 FY2026

Millions
Total revenues
0
Gross profit
0
Operating income
(0)
Net income
0
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2022 to FY2025
+2.1%
Revenue, 5 yearsFY2020 to FY2025
+2.3%
Net income, 5 yearsFY2020 to FY2025
n/m

BIOADAPTIVES, INC. (BDPT) financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2025FY2024ChangeSource
Revenue$18,278$12,669+44.3%10-K 2026-04-14 · proof
Gross profit$12,497$4,030+210.1%10-K 2026-04-14 · proof
Operating income-$1 million-$602,09010-K 2026-04-14 · proof
Net income-$1.6 million-$899,16110-K 2026-04-14 · proof
Cash from operating activities-$516,025-$249,51710-K 2026-04-14 · proof
Free cash flow-$534,025-$249,51710-K 2026-04-14 · proof
Total assets$225,901$261,885-13.7%10-K 2026-04-14 · proof
Total liabilities$2.4 million$1.7 million+36.5%10-K 2026-04-14 · proof
Cash and cash equivalents$215,205$261,885-17.8%10-K 2026-04-14 · proof
What was BIOADAPTIVES, INC. (BDPT)'s revenue in fiscal 2025?
BIOADAPTIVES, INC. (BDPT) reported revenue of $18,278 for fiscal 2025 (the year ended Dec 31, 2025), against $12,669 the year before (+44.3%). Source: the 10-K filed with the SEC on Apr 14, 2026. SEC
What was BIOADAPTIVES, INC. (BDPT)'s gross profit in fiscal 2025?
BIOADAPTIVES, INC. (BDPT) reported gross profit of $12,497 for fiscal 2025 (the year ended Dec 31, 2025), against $4,030 the year before (+210.1%). Source: the 10-K filed with the SEC on Apr 14, 2026. SEC
What was BIOADAPTIVES, INC. (BDPT)'s operating income in fiscal 2025?
BIOADAPTIVES, INC. (BDPT) reported operating income of -$1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$602,090 the year before. Source: the 10-K filed with the SEC on Apr 14, 2026. SEC
What was BIOADAPTIVES, INC. (BDPT)'s net income in fiscal 2025?
BIOADAPTIVES, INC. (BDPT) reported net income of -$1.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$899,161 the year before. Source: the 10-K filed with the SEC on Apr 14, 2026. SEC
What was BIOADAPTIVES, INC. (BDPT)'s cash from operating activities in fiscal 2025?
BIOADAPTIVES, INC. (BDPT) reported cash from operating activities of -$516,025 for fiscal 2025 (the year ended Dec 31, 2025), against -$249,517 the year before. Source: the 10-K filed with the SEC on Apr 14, 2026. SEC
What was BIOADAPTIVES, INC. (BDPT)'s free cash flow in fiscal 2025?
BIOADAPTIVES, INC. (BDPT) reported free cash flow of -$534,025 for fiscal 2025 (the year ended Dec 31, 2025), against -$249,517 the year before. Source: the 10-K filed with the SEC on Apr 14, 2026. SEC
What are BIOADAPTIVES, INC. (BDPT)'s total assets?
As of Dec 31, 2025, BIOADAPTIVES, INC. (BDPT) reported total assets of $225,901, against $261,885 a year earlier (-13.7%). Source: the 10-K filed with the SEC on Apr 14, 2026. SEC
What are BIOADAPTIVES, INC. (BDPT)'s total liabilities?
As of Dec 31, 2025, BIOADAPTIVES, INC. (BDPT) reported total liabilities of $2.4 million, against $1.7 million a year earlier (+36.5%). Source: the 10-K filed with the SEC on Apr 14, 2026. SEC
What are BIOADAPTIVES, INC. (BDPT)'s cash and cash equivalents?
As of Dec 31, 2025, BIOADAPTIVES, INC. (BDPT) reported cash and cash equivalents of $215,205, against $261,885 a year earlier (-17.8%). Source: the 10-K filed with the SEC on Apr 14, 2026. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:BDPT&period_type=annual&limit=5"

Information only, not investment advice.